Caribou reports Q2 2026 results, updates vispa-cel and CB-011 data

Caribou Biosciences reported second-quarter 2026 financial results and a pipeline update on August 13, 2026. The company said it previously reached alignment with the FDA regarding its planned ANTLER-3 pivotal phase 3 trial, expected to be a randomized, controlled study enrolling approximately 250 CD19-naive second-line LBCL patients who are not eligible for transplant and not candidates or not eligible for autologous CAR-T cell therapy based on access challenges or medical criteria, including urgent need for therapy.¹

For vispa-cel, updated ANTLER phase 1 data presented in June at the EHA 2026 meeting showed that among 27 second-line LBCL patients who got a single 80 million cell dose, the overall response rate was 82%, the complete response rate was 67%, and median progression-free survival reached 17.1 months, with a generally well-tolerated safety profile.¹

For CB-011 in relapsed or refractory multiple myeloma, CaMMouflage phase 1 data on 12 BCMA-naive patients treated at the recommended expansion dose of 450 million cells showed a 92% overall response rate, an 83% complete or stringent complete response rate, 91% MRD negativity in 10 of 11 evaluable patients, and 50% of patients in complete or stringent complete response at 15 months, with a manageable safety profile.¹ Caribou said it expects to report initial safety and efficacy data from more than 15 dose-expansion patients with at least three months of follow-up, along with longer follow-up on the 12-patient dose-escalation cohort, in the second half of 2026.¹

On finances, the company held $113.8 million in cash, cash equivalents, and marketable securities as of June 30, 2026, versus $142.8 million at the end of 2025.¹ Caribou said it now expects this cash to fund operations, including CB-011 dose expansion and ANTLER-3 start-up activities, to the end of 2027, while it explores options to fully fund the ANTLER-3 trial.¹